Blue Owl Capital Holdings LP has made a significant investment in KalVista Pharmaceuticals, Inc., acquiring 125,000 shares valued at approximately $1.52 million. This transaction took place during the third quarter of 2024, according to information from HoldingsChannel.com. The investment reflects growing interest among institutional investors in the pharmaceutical sector.
Other hedge funds have also adjusted their positions in KalVista Pharmaceuticals recently. The Manufacturers Life Insurance Company increased its stake by 5.9% in the second quarter, now holding 14,626 shares worth about $165,000 after adding 818 shares. Similarly, BNP Paribas Financial Markets boosted its holdings by an impressive 47.0%, acquiring an additional 1,292 shares, bringing its total to 4,041 shares valued at $46,000.
Additionally, Rhumbline Advisers raised its stake by 2.8%, now owning 54,376 shares valued at $615,000. The Police & Firemen’s Retirement System of New Jersey also increased its position by 26.8%, with 9,756 shares worth $110,000 following the purchase of 2,061 shares. Finally, Profund Advisors LLC reported a 25.9% increase in its holdings, now owning 12,613 shares valued at $154,000.
Recent Insider Transactions
In related developments, Brian Piekos, the Chief Financial Officer of KalVista, sold 1,767 shares on February 23, 2024, at an average price of $15.57, generating a total of $27,512.19. Following this transaction, he retains 13,762 shares valued at approximately $214,274.34, marking an 11.38% decrease in his holdings.
Another insider, Paul K. Audhya, also sold shares on the same date, offloading 5,354 shares for a total of $83,361.78. After the sale, he holds 138,983 shares valued at $2,163,965.31, reflecting a 3.71% decrease in his position. Across the last three months, insiders have sold a total of 33,979 shares worth $535,091, with insiders collectively owning 4.30% of the company’s stock.
KalVista Pharmaceuticals Overview
As of the latest trading session, shares of KalVista Pharmaceuticals opened at $16.23. The company’s stock has shown a modest increase of 0.1% recently. KalVista’s 50-day simple moving average stands at $15.57, while its 200-day average is $14.11. With a market capitalization of $820.43 million, the company has a P/E ratio of -4.11 and a beta of -0.35. It also reports a debt-to-equity ratio of 8.18, along with a quick ratio of 7.21.
KalVista Pharmaceuticals focuses on the development of small-molecule protease inhibitors targeting orphan and specialty diseases. The company’s scientific platform emphasizes the selective inhibition of plasma kallikrein, a serine protease associated with conditions that involve vascular leak, edema, and inflammation. Its lead programs include an oral plasma kallikrein inhibitor in clinical trials designed for the acute treatment of hereditary angioedema (HAE) attacks, as well as an intravitreal kallikrein inhibitor aimed at diabetic macular edema.
For those interested in following additional hedge fund movements regarding KalVista Pharmaceuticals, HoldingsChannel.com provides updated 13F filings and insider trades.
